Moderna enters growth phase with new equity financing and BARDA grant for Zika mRNA vaccine

8 September 2016

US clinical-stage biotech firm Moderna Therapeutics, which is pioneering modified messenger RNA (mRNA) therapeutics to create a new generation of transformative medicines for patients, announced today that it has raised $474 million.

This latest equity financing includes strong support from existing institutional investors and world-class strategic pharmaceutical partners as well as participation of new institutional investors from the USA, Europe and Asia.

Last month, AstraZeneca (LSE: AZN) increased its equity interest Moderna Therapeutics with a $140 million investment as part of Moderna’s preferred-stock financing, bringing its stake in the company to 9%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK